drugset / Trial / NCT00314626

Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily

NCT00314626

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the proportion of patients with virological failure after 48 weeks of treatment with the combination of efavirenz 600 mg + lamivudine (3TC) 300 mg + abacavir 600 mg once daily as an antiretroviral simplification regimen.

Timeline

Start
2004-11
Primary completion
2007-02
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 600 mg
Subject Efavirenz Other / unclassified 600 mg
Subject Lamivudine Other / unclassified 300 mg